nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC22A5—Diphenhydramine—atopic dermatitis	0.208	0.44	CbGbCtD
Amphetamine—Benzphetamine—Diphenhydramine—atopic dermatitis	0.16	1	CrCrCtD
Amphetamine—CYP2A6—Prednisolone—atopic dermatitis	0.0926	0.197	CbGbCtD
Amphetamine—CYP2A6—Dexamethasone—atopic dermatitis	0.0546	0.116	CbGbCtD
Amphetamine—CYP2D6—Loratadine—atopic dermatitis	0.0496	0.105	CbGbCtD
Amphetamine—CYP2D6—Diphenhydramine—atopic dermatitis	0.0496	0.105	CbGbCtD
Amphetamine—CYP2D6—Dexamethasone—atopic dermatitis	0.0172	0.0364	CbGbCtD
Amphetamine—CARTPT—Circadian rythm related genes—RELB—atopic dermatitis	0.00634	0.137	CbGpPWpGaD
Amphetamine—SLC22A5—Temsirolimus—Tacrolimus—atopic dermatitis	0.00428	0.5	CbGdCrCtD
Amphetamine—SLC22A5—Temsirolimus—Pimecrolimus—atopic dermatitis	0.00428	0.5	CbGdCrCtD
Amphetamine—Pseudoephedrine—IL2—atopic dermatitis	0.00262	0.747	CrCbGaD
Amphetamine—CARTPT—Circadian rythm related genes—NPS—atopic dermatitis	0.00225	0.0485	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—PPARA—atopic dermatitis	0.00133	0.0286	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCL22—atopic dermatitis	0.000889	0.0192	CbGpPWpGaD
Amphetamine—Pseudoephedrine—TNF—atopic dermatitis	0.000886	0.252	CrCbGaD
Amphetamine—TAAR1—G alpha (s) signalling events—NPS—atopic dermatitis	0.000874	0.0188	CbGpPWpGaD
Amphetamine—SLC6A4—Serotonin Transporter Activity—IL1B—atopic dermatitis	0.000825	0.0178	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCL27—atopic dermatitis	0.000793	0.0171	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—MAPK8—atopic dermatitis	0.000736	0.0159	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCL17—atopic dermatitis	0.000711	0.0153	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—CCL22—atopic dermatitis	0.000677	0.0146	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—RELB—atopic dermatitis	0.000638	0.0137	CbGpPWpGaD
Amphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—atopic dermatitis	0.00063	0.0136	CbGpPWpGaD
Amphetamine—Body temperature increased—Fluocinolone Acetonide—atopic dermatitis	0.000619	0.002	CcSEcCtD
Amphetamine—Anxiety—Tacrolimus—atopic dermatitis	0.000619	0.002	CcSEcCtD
Amphetamine—Irritability—Dexamethasone—atopic dermatitis	0.000616	0.00199	CcSEcCtD
Amphetamine—Irritability—Betamethasone—atopic dermatitis	0.000616	0.00199	CcSEcCtD
Amphetamine—Injury—Prednisone—atopic dermatitis	0.000612	0.00197	CcSEcCtD
Amphetamine—Gastrointestinal pain—Mometasone—atopic dermatitis	0.000612	0.00197	CcSEcCtD
Amphetamine—Mood swings—Betamethasone—atopic dermatitis	0.000611	0.00197	CcSEcCtD
Amphetamine—Mood swings—Dexamethasone—atopic dermatitis	0.000611	0.00197	CcSEcCtD
Amphetamine—Dry mouth—Tacrolimus—atopic dermatitis	0.000607	0.00196	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—CCL27—atopic dermatitis	0.000604	0.013	CbGpPWpGaD
Amphetamine—Diarrhoea—Loratadine—atopic dermatitis	0.000596	0.00193	CcSEcCtD
Amphetamine—Anaphylactic shock—Tacrolimus—atopic dermatitis	0.000595	0.00192	CcSEcCtD
Amphetamine—Infection—Tacrolimus—atopic dermatitis	0.000591	0.00191	CcSEcCtD
Amphetamine—Body temperature increased—Mometasone—atopic dermatitis	0.000591	0.00191	CcSEcCtD
Amphetamine—Abdominal pain—Mometasone—atopic dermatitis	0.000591	0.00191	CcSEcCtD
Amphetamine—Weight decreased—Hydrocortisone—atopic dermatitis	0.000591	0.00191	CcSEcCtD
Amphetamine—Acute coronary syndrome—Prednisolone—atopic dermatitis	0.000588	0.0019	CcSEcCtD
Amphetamine—Myocardial infarction—Prednisolone—atopic dermatitis	0.000584	0.00189	CcSEcCtD
Amphetamine—Tachycardia—Tacrolimus—atopic dermatitis	0.000581	0.00188	CcSEcCtD
Amphetamine—Hypersensitivity—Fluocinolone Acetonide—atopic dermatitis	0.000577	0.00186	CcSEcCtD
Amphetamine—Dizziness—Loratadine—atopic dermatitis	0.000576	0.00186	CcSEcCtD
Amphetamine—Hyperhidrosis—Tacrolimus—atopic dermatitis	0.000575	0.00186	CcSEcCtD
Amphetamine—Acute coronary syndrome—Hydrocortisone—atopic dermatitis	0.000574	0.00185	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCL11—atopic dermatitis	0.000573	0.0123	CbGpPWpGaD
Amphetamine—Myocardial infarction—Hydrocortisone—atopic dermatitis	0.000571	0.00184	CcSEcCtD
Amphetamine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—atopic dermatitis	0.000568	0.0122	CbGpPWpGaD
Amphetamine—Anorexia—Tacrolimus—atopic dermatitis	0.000567	0.00183	CcSEcCtD
Amphetamine—Vomiting—Loratadine—atopic dermatitis	0.000554	0.00179	CcSEcCtD
Amphetamine—Affect lability—Prednisone—atopic dermatitis	0.000553	0.00179	CcSEcCtD
Amphetamine—Rash—Loratadine—atopic dermatitis	0.000549	0.00177	CcSEcCtD
Amphetamine—Psychotic disorder—Prednisone—atopic dermatitis	0.000549	0.00177	CcSEcCtD
Amphetamine—Dermatitis—Loratadine—atopic dermatitis	0.000549	0.00177	CcSEcCtD
Amphetamine—Headache—Loratadine—atopic dermatitis	0.000546	0.00176	CcSEcCtD
Amphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—atopic dermatitis	0.000545	0.0117	CbGpPWpGaD
Amphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—atopic dermatitis	0.000543	0.0117	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—CCL17—atopic dermatitis	0.000542	0.0117	CbGpPWpGaD
Amphetamine—Acute coronary syndrome—Triamcinolone—atopic dermatitis	0.00054	0.00175	CcSEcCtD
Amphetamine—Acute coronary syndrome—Methylprednisolone—atopic dermatitis	0.000539	0.00174	CcSEcCtD
Amphetamine—Insomnia—Tacrolimus—atopic dermatitis	0.000538	0.00174	CcSEcCtD
Amphetamine—Myocardial infarction—Triamcinolone—atopic dermatitis	0.000537	0.00174	CcSEcCtD
Amphetamine—Asthenia—Mometasone—atopic dermatitis	0.000537	0.00173	CcSEcCtD
Amphetamine—Irritability—Prednisone—atopic dermatitis	0.000536	0.00173	CcSEcCtD
Amphetamine—Myocardial infarction—Methylprednisolone—atopic dermatitis	0.000536	0.00173	CcSEcCtD
Amphetamine—Diarrhoea—Fluocinolone Acetonide—atopic dermatitis	0.000536	0.00173	CcSEcCtD
Amphetamine—Mood swings—Prednisone—atopic dermatitis	0.000532	0.00172	CcSEcCtD
Amphetamine—Dyspnoea—Tacrolimus—atopic dermatitis	0.000531	0.00171	CcSEcCtD
Amphetamine—Somnolence—Tacrolimus—atopic dermatitis	0.000529	0.00171	CcSEcCtD
Amphetamine—Sweating—Methylprednisolone—atopic dermatitis	0.000524	0.00169	CcSEcCtD
Amphetamine—Dyspepsia—Tacrolimus—atopic dermatitis	0.000524	0.00169	CcSEcCtD
Amphetamine—Dizziness—Fluocinolone Acetonide—atopic dermatitis	0.000518	0.00167	CcSEcCtD
Amphetamine—Nausea—Loratadine—atopic dermatitis	0.000518	0.00167	CcSEcCtD
Amphetamine—Decreased appetite—Tacrolimus—atopic dermatitis	0.000517	0.00167	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Tacrolimus—atopic dermatitis	0.000514	0.00166	CcSEcCtD
Amphetamine—Fatigue—Tacrolimus—atopic dermatitis	0.000513	0.00166	CcSEcCtD
Amphetamine—Diarrhoea—Mometasone—atopic dermatitis	0.000512	0.00165	CcSEcCtD
Amphetamine—Constipation—Tacrolimus—atopic dermatitis	0.000509	0.00164	CcSEcCtD
Amphetamine—Weight decreased—Dexamethasone—atopic dermatitis	0.000505	0.00163	CcSEcCtD
Amphetamine—Weight decreased—Betamethasone—atopic dermatitis	0.000505	0.00163	CcSEcCtD
Amphetamine—Vomiting—Fluocinolone Acetonide—atopic dermatitis	0.000498	0.00161	CcSEcCtD
Amphetamine—Rash—Fluocinolone Acetonide—atopic dermatitis	0.000494	0.00159	CcSEcCtD
Amphetamine—Dermatitis—Fluocinolone Acetonide—atopic dermatitis	0.000493	0.00159	CcSEcCtD
Amphetamine—Headache—Fluocinolone Acetonide—atopic dermatitis	0.000491	0.00158	CcSEcCtD
Amphetamine—Acute coronary syndrome—Betamethasone—atopic dermatitis	0.00049	0.00158	CcSEcCtD
Amphetamine—Acute coronary syndrome—Dexamethasone—atopic dermatitis	0.00049	0.00158	CcSEcCtD
Amphetamine—Myocardial infarction—Dexamethasone—atopic dermatitis	0.000488	0.00157	CcSEcCtD
Amphetamine—Myocardial infarction—Betamethasone—atopic dermatitis	0.000488	0.00157	CcSEcCtD
Amphetamine—Gastrointestinal pain—Tacrolimus—atopic dermatitis	0.000487	0.00157	CcSEcCtD
Amphetamine—Vomiting—Mometasone—atopic dermatitis	0.000475	0.00154	CcSEcCtD
Amphetamine—Urticaria—Tacrolimus—atopic dermatitis	0.000473	0.00153	CcSEcCtD
Amphetamine—Rash—Mometasone—atopic dermatitis	0.000472	0.00152	CcSEcCtD
Amphetamine—Dermatitis—Mometasone—atopic dermatitis	0.000471	0.00152	CcSEcCtD
Amphetamine—Body temperature increased—Tacrolimus—atopic dermatitis	0.000471	0.00152	CcSEcCtD
Amphetamine—Abdominal pain—Tacrolimus—atopic dermatitis	0.000471	0.00152	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—IL6—atopic dermatitis	0.00047	0.0101	CbGpPWpGaD
Amphetamine—Headache—Mometasone—atopic dermatitis	0.000468	0.00151	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCR3—atopic dermatitis	0.000467	0.0101	CbGpPWpGaD
Amphetamine—Nausea—Fluocinolone Acetonide—atopic dermatitis	0.000465	0.0015	CcSEcCtD
Amphetamine—Erectile dysfunction—Prednisone—atopic dermatitis	0.000447	0.00144	CcSEcCtD
Amphetamine—Nausea—Mometasone—atopic dermatitis	0.000444	0.00143	CcSEcCtD
Amphetamine—Weight decreased—Prednisone—atopic dermatitis	0.00044	0.00142	CcSEcCtD
Amphetamine—Hypersensitivity—Tacrolimus—atopic dermatitis	0.000439	0.00142	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—CCL11—atopic dermatitis	0.000436	0.0094	CbGpPWpGaD
Amphetamine—Depression—Prednisone—atopic dermatitis	0.000432	0.00139	CcSEcCtD
Amphetamine—Asthenia—Tacrolimus—atopic dermatitis	0.000427	0.00138	CcSEcCtD
Amphetamine—Acute coronary syndrome—Prednisone—atopic dermatitis	0.000427	0.00138	CcSEcCtD
Amphetamine—Angioedema—Prednisolone—atopic dermatitis	0.000426	0.00137	CcSEcCtD
Amphetamine—Myocardial infarction—Prednisone—atopic dermatitis	0.000425	0.00137	CcSEcCtD
Amphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—atopic dermatitis	0.000424	0.00914	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—TAC1—atopic dermatitis	0.000416	0.00897	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—NPS—atopic dermatitis	0.000416	0.00897	CbGpPWpGaD
Amphetamine—Angioedema—Hydrocortisone—atopic dermatitis	0.000416	0.00134	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—atopic dermatitis	0.000408	0.0088	CbGpPWpGaD
Amphetamine—Diarrhoea—Tacrolimus—atopic dermatitis	0.000407	0.00132	CcSEcCtD
Amphetamine—Convulsion—Prednisolone—atopic dermatitis	0.000404	0.0013	CcSEcCtD
Amphetamine—Hypertension—Prednisolone—atopic dermatitis	0.000402	0.0013	CcSEcCtD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—TRPV3—atopic dermatitis	0.000396	0.00854	CbGpPWpGaD
Amphetamine—Convulsion—Hydrocortisone—atopic dermatitis	0.000394	0.00127	CcSEcCtD
Amphetamine—Dizziness—Tacrolimus—atopic dermatitis	0.000394	0.00127	CcSEcCtD
Amphetamine—Hypertension—Hydrocortisone—atopic dermatitis	0.000393	0.00127	CcSEcCtD
Amphetamine—Angioedema—Triamcinolone—atopic dermatitis	0.000391	0.00126	CcSEcCtD
Amphetamine—Angioedema—Methylprednisolone—atopic dermatitis	0.000391	0.00126	CcSEcCtD
Amphetamine—DRD2—Circadian rythm related genes—RELB—atopic dermatitis	0.00039	0.00841	CbGpPWpGaD
Amphetamine—Anxiety—Hydrocortisone—atopic dermatitis	0.000386	0.00125	CcSEcCtD
Amphetamine—Anaphylactic shock—Prednisolone—atopic dermatitis	0.00038	0.00123	CcSEcCtD
Amphetamine—Vomiting—Tacrolimus—atopic dermatitis	0.000378	0.00122	CcSEcCtD
Amphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—atopic dermatitis	0.000376	0.00809	CbGpPWpGaD
Amphetamine—Rash—Tacrolimus—atopic dermatitis	0.000375	0.00121	CcSEcCtD
Amphetamine—Dermatitis—Tacrolimus—atopic dermatitis	0.000375	0.00121	CcSEcCtD
Amphetamine—Headache—Tacrolimus—atopic dermatitis	0.000373	0.0012	CcSEcCtD
Amphetamine—Anaphylactic shock—Hydrocortisone—atopic dermatitis	0.000371	0.0012	CcSEcCtD
Amphetamine—Convulsion—Triamcinolone—atopic dermatitis	0.000371	0.0012	CcSEcCtD
Amphetamine—Tachycardia—Prednisolone—atopic dermatitis	0.000371	0.0012	CcSEcCtD
Amphetamine—Convulsion—Methylprednisolone—atopic dermatitis	0.00037	0.0012	CcSEcCtD
Amphetamine—Hypertension—Triamcinolone—atopic dermatitis	0.00037	0.00119	CcSEcCtD
Amphetamine—Hypertension—Methylprednisolone—atopic dermatitis	0.000369	0.00119	CcSEcCtD
Amphetamine—Infection—Hydrocortisone—atopic dermatitis	0.000369	0.00119	CcSEcCtD
Amphetamine—Hyperhidrosis—Prednisolone—atopic dermatitis	0.000368	0.00119	CcSEcCtD
Amphetamine—Anxiety—Methylprednisolone—atopic dermatitis	0.000363	0.00117	CcSEcCtD
Amphetamine—Tachycardia—Hydrocortisone—atopic dermatitis	0.000362	0.00117	CcSEcCtD
Amphetamine—Hyperhidrosis—Hydrocortisone—atopic dermatitis	0.000359	0.00116	CcSEcCtD
Amphetamine—Dry mouth—Triamcinolone—atopic dermatitis	0.000357	0.00115	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—CCR3—atopic dermatitis	0.000356	0.00767	CbGpPWpGaD
Amphetamine—Angioedema—Betamethasone—atopic dermatitis	0.000355	0.00115	CcSEcCtD
Amphetamine—Angioedema—Dexamethasone—atopic dermatitis	0.000355	0.00115	CcSEcCtD
Amphetamine—Anorexia—Hydrocortisone—atopic dermatitis	0.000354	0.00114	CcSEcCtD
Amphetamine—Nausea—Tacrolimus—atopic dermatitis	0.000354	0.00114	CcSEcCtD
Amphetamine—SLC6A4—Monoamine Transport—IL1B—atopic dermatitis	0.000351	0.00756	CbGpPWpGaD
Amphetamine—Anaphylactic shock—Triamcinolone—atopic dermatitis	0.00035	0.00113	CcSEcCtD
Amphetamine—Anaphylactic shock—Methylprednisolone—atopic dermatitis	0.000349	0.00113	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—CCL22—atopic dermatitis	0.000348	0.00749	CbGpPWpGaD
Amphetamine—Infection—Triamcinolone—atopic dermatitis	0.000347	0.00112	CcSEcCtD
Amphetamine—Infection—Methylprednisolone—atopic dermatitis	0.000347	0.00112	CcSEcCtD
Amphetamine—Insomnia—Prednisolone—atopic dermatitis	0.000344	0.00111	CcSEcCtD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—TRPV3—atopic dermatitis	0.000343	0.00739	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—TRPV3—atopic dermatitis	0.000342	0.00736	CbGpPWpGaD
Amphetamine—Tachycardia—Triamcinolone—atopic dermatitis	0.000341	0.0011	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—CCL27—atopic dermatitis	0.000341	0.00735	CbGpPWpGaD
Amphetamine—Tachycardia—Methylprednisolone—atopic dermatitis	0.00034	0.0011	CcSEcCtD
Amphetamine—Hyperhidrosis—Triamcinolone—atopic dermatitis	0.000338	0.00109	CcSEcCtD
Amphetamine—Hyperhidrosis—Methylprednisolone—atopic dermatitis	0.000337	0.00109	CcSEcCtD
Amphetamine—Convulsion—Dexamethasone—atopic dermatitis	0.000337	0.00109	CcSEcCtD
Amphetamine—Convulsion—Betamethasone—atopic dermatitis	0.000337	0.00109	CcSEcCtD
Amphetamine—Insomnia—Hydrocortisone—atopic dermatitis	0.000336	0.00108	CcSEcCtD
Amphetamine—Hypertension—Dexamethasone—atopic dermatitis	0.000336	0.00108	CcSEcCtD
Amphetamine—Hypertension—Betamethasone—atopic dermatitis	0.000336	0.00108	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCL10—atopic dermatitis	0.00033	0.00711	CbGpPWpGaD
Amphetamine—Anxiety—Dexamethasone—atopic dermatitis	0.00033	0.00106	CcSEcCtD
Amphetamine—Anxiety—Betamethasone—atopic dermatitis	0.00033	0.00106	CcSEcCtD
Amphetamine—Dyspepsia—Hydrocortisone—atopic dermatitis	0.000327	0.00106	CcSEcCtD
Amphetamine—Decreased appetite—Hydrocortisone—atopic dermatitis	0.000323	0.00104	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	0.000321	0.00104	CcSEcCtD
Amphetamine—Fatigue—Hydrocortisone—atopic dermatitis	0.00032	0.00103	CcSEcCtD
Amphetamine—Anaphylactic shock—Dexamethasone—atopic dermatitis	0.000317	0.00102	CcSEcCtD
Amphetamine—Anaphylactic shock—Betamethasone—atopic dermatitis	0.000317	0.00102	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—NPS—atopic dermatitis	0.000317	0.00683	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—TAC1—atopic dermatitis	0.000317	0.00683	CbGpPWpGaD
Amphetamine—Insomnia—Triamcinolone—atopic dermatitis	0.000316	0.00102	CcSEcCtD
Amphetamine—Insomnia—Methylprednisolone—atopic dermatitis	0.000316	0.00102	CcSEcCtD
Amphetamine—Infection—Dexamethasone—atopic dermatitis	0.000315	0.00102	CcSEcCtD
Amphetamine—Infection—Betamethasone—atopic dermatitis	0.000315	0.00102	CcSEcCtD
Amphetamine—Dyspnoea—Triamcinolone—atopic dermatitis	0.000312	0.00101	CcSEcCtD
Amphetamine—Agitation—Prednisone—atopic dermatitis	0.000311	0.001	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—CXCR3—atopic dermatitis	0.000311	0.0067	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CCL27—atopic dermatitis	0.00031	0.00668	CbGpPWpGaD
Amphetamine—Tachycardia—Dexamethasone—atopic dermatitis	0.00031	0.001	CcSEcCtD
Amphetamine—Tachycardia—Betamethasone—atopic dermatitis	0.00031	0.001	CcSEcCtD
Amphetamine—Angioedema—Prednisone—atopic dermatitis	0.000309	0.000999	CcSEcCtD
Amphetamine—Dyspepsia—Triamcinolone—atopic dermatitis	0.000308	0.000994	CcSEcCtD
Amphetamine—Dyspepsia—Methylprednisolone—atopic dermatitis	0.000307	0.000992	CcSEcCtD
Amphetamine—Hyperhidrosis—Dexamethasone—atopic dermatitis	0.000307	0.00099	CcSEcCtD
Amphetamine—Hyperhidrosis—Betamethasone—atopic dermatitis	0.000307	0.00099	CcSEcCtD
Amphetamine—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	0.000304	0.000981	CcSEcCtD
Amphetamine—Anorexia—Dexamethasone—atopic dermatitis	0.000302	0.000977	CcSEcCtD
Amphetamine—Anorexia—Betamethasone—atopic dermatitis	0.000302	0.000977	CcSEcCtD
Amphetamine—Urticaria—Prednisolone—atopic dermatitis	0.000302	0.000975	CcSEcCtD
Amphetamine—SLC6A2—Monoamine Transport—IL1B—atopic dermatitis	0.000302	0.0065	CbGpPWpGaD
Amphetamine—Fatigue—Triamcinolone—atopic dermatitis	0.000301	0.000973	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL13—atopic dermatitis	0.000301	0.00649	CbGpPWpGaD
Amphetamine—Fatigue—Methylprednisolone—atopic dermatitis	0.000301	0.000971	CcSEcCtD
Amphetamine—Urticaria—Hydrocortisone—atopic dermatitis	0.000295	0.000953	CcSEcCtD
Amphetamine—Abdominal pain—Hydrocortisone—atopic dermatitis	0.000294	0.000948	CcSEcCtD
Amphetamine—Body temperature increased—Hydrocortisone—atopic dermatitis	0.000294	0.000948	CcSEcCtD
Amphetamine—Convulsion—Prednisone—atopic dermatitis	0.000293	0.000947	CcSEcCtD
Amphetamine—Hypertension—Prednisone—atopic dermatitis	0.000292	0.000944	CcSEcCtD
Amphetamine—Anxiety—Prednisone—atopic dermatitis	0.000287	0.000927	CcSEcCtD
Amphetamine—Insomnia—Betamethasone—atopic dermatitis	0.000287	0.000927	CcSEcCtD
Amphetamine—Insomnia—Dexamethasone—atopic dermatitis	0.000287	0.000927	CcSEcCtD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC11A1—atopic dermatitis	0.000286	0.00617	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	0.000285	0.000921	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCL5—atopic dermatitis	0.000284	0.00612	CbGpPWpGaD
Amphetamine—Hypersensitivity—Prednisolone—atopic dermatitis	0.00028	0.000905	CcSEcCtD
Amphetamine—Dyspepsia—Dexamethasone—atopic dermatitis	0.000279	0.000902	CcSEcCtD
Amphetamine—Dyspepsia—Betamethasone—atopic dermatitis	0.000279	0.000902	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—CCL17—atopic dermatitis	0.000278	0.00599	CbGpPWpGaD
Amphetamine—Urticaria—Triamcinolone—atopic dermatitis	0.000278	0.000897	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—TAC1—atopic dermatitis	0.000277	0.00597	CbGpPWpGaD
Amphetamine—Urticaria—Methylprednisolone—atopic dermatitis	0.000277	0.000895	CcSEcCtD
Amphetamine—Body temperature increased—Triamcinolone—atopic dermatitis	0.000276	0.000893	CcSEcCtD
Amphetamine—Anaphylactic shock—Prednisone—atopic dermatitis	0.000276	0.000892	CcSEcCtD
Amphetamine—Abdominal pain—Methylprednisolone—atopic dermatitis	0.000276	0.000891	CcSEcCtD
Amphetamine—Decreased appetite—Dexamethasone—atopic dermatitis	0.000276	0.000891	CcSEcCtD
Amphetamine—Decreased appetite—Betamethasone—atopic dermatitis	0.000276	0.000891	CcSEcCtD
Amphetamine—Infection—Prednisone—atopic dermatitis	0.000274	0.000886	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	0.000274	0.000884	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Betamethasone—atopic dermatitis	0.000274	0.000884	CcSEcCtD
Amphetamine—Hypersensitivity—Hydrocortisone—atopic dermatitis	0.000274	0.000883	CcSEcCtD
Amphetamine—Fatigue—Betamethasone—atopic dermatitis	0.000273	0.000883	CcSEcCtD
Amphetamine—Fatigue—Dexamethasone—atopic dermatitis	0.000273	0.000883	CcSEcCtD
Amphetamine—Tachycardia—Prednisone—atopic dermatitis	0.00027	0.000871	CcSEcCtD
Amphetamine—SLC6A3—Monoamine Transport—IL1B—atopic dermatitis	0.000267	0.00576	CbGpPWpGaD
Amphetamine—Hyperhidrosis—Prednisone—atopic dermatitis	0.000267	0.000862	CcSEcCtD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—TRPV3—atopic dermatitis	0.000267	0.00575	CbGpPWpGaD
Amphetamine—Asthenia—Hydrocortisone—atopic dermatitis	0.000266	0.00086	CcSEcCtD
Amphetamine—Anorexia—Prednisone—atopic dermatitis	0.000263	0.00085	CcSEcCtD
Amphetamine—Gastrointestinal pain—Dexamethasone—atopic dermatitis	0.000259	0.000838	CcSEcCtD
Amphetamine—Gastrointestinal pain—Betamethasone—atopic dermatitis	0.000259	0.000838	CcSEcCtD
Amphetamine—Hypersensitivity—Triamcinolone—atopic dermatitis	0.000258	0.000832	CcSEcCtD
Amphetamine—Hypersensitivity—Methylprednisolone—atopic dermatitis	0.000257	0.00083	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	0.000256	0.00552	CbGpPWpGaD
Amphetamine—SLC6A4—Monoamine Transport—TNF—atopic dermatitis	0.000255	0.00549	CbGpPWpGaD
Amphetamine—Diarrhoea—Hydrocortisone—atopic dermatitis	0.000254	0.00082	CcSEcCtD
Amphetamine—Urticaria—Dexamethasone—atopic dermatitis	0.000252	0.000814	CcSEcCtD
Amphetamine—Urticaria—Betamethasone—atopic dermatitis	0.000252	0.000814	CcSEcCtD
Amphetamine—Dizziness—Prednisolone—atopic dermatitis	0.000251	0.000812	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—CXCL10—atopic dermatitis	0.000251	0.00542	CbGpPWpGaD
Amphetamine—Asthenia—Triamcinolone—atopic dermatitis	0.000251	0.00081	CcSEcCtD
Amphetamine—Abdominal pain—Betamethasone—atopic dermatitis	0.000251	0.00081	CcSEcCtD
Amphetamine—Body temperature increased—Dexamethasone—atopic dermatitis	0.000251	0.00081	CcSEcCtD
Amphetamine—Body temperature increased—Betamethasone—atopic dermatitis	0.000251	0.00081	CcSEcCtD
Amphetamine—Abdominal pain—Dexamethasone—atopic dermatitis	0.000251	0.00081	CcSEcCtD
Amphetamine—Asthenia—Methylprednisolone—atopic dermatitis	0.00025	0.000808	CcSEcCtD
Amphetamine—Insomnia—Prednisone—atopic dermatitis	0.00025	0.000807	CcSEcCtD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC11A1—atopic dermatitis	0.000248	0.00534	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC11A1—atopic dermatitis	0.000247	0.00532	CbGpPWpGaD
Amphetamine—Dizziness—Hydrocortisone—atopic dermatitis	0.000246	0.000793	CcSEcCtD
Amphetamine—Dyspepsia—Prednisone—atopic dermatitis	0.000243	0.000785	CcSEcCtD
Amphetamine—Decreased appetite—Prednisone—atopic dermatitis	0.00024	0.000776	CcSEcCtD
Amphetamine—Rash—Prednisolone—atopic dermatitis	0.00024	0.000774	CcSEcCtD
Amphetamine—Dermatitis—Prednisolone—atopic dermatitis	0.000239	0.000773	CcSEcCtD
Amphetamine—Diarrhoea—Methylprednisolone—atopic dermatitis	0.000239	0.000771	CcSEcCtD
Amphetamine—Fatigue—Prednisone—atopic dermatitis	0.000238	0.000769	CcSEcCtD
Amphetamine—Headache—Prednisolone—atopic dermatitis	0.000238	0.000769	CcSEcCtD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—TRPV3—atopic dermatitis	0.000236	0.00509	CbGpPWpGaD
Amphetamine—Constipation—Prednisone—atopic dermatitis	0.000236	0.000763	CcSEcCtD
Amphetamine—Vomiting—Hydrocortisone—atopic dermatitis	0.000236	0.000762	CcSEcCtD
Amphetamine—Rash—Hydrocortisone—atopic dermatitis	0.000234	0.000756	CcSEcCtD
Amphetamine—Dermatitis—Hydrocortisone—atopic dermatitis	0.000234	0.000755	CcSEcCtD
Amphetamine—Headache—Hydrocortisone—atopic dermatitis	0.000233	0.000751	CcSEcCtD
Amphetamine—DRD2—G alpha (i) signalling events—CCL27—atopic dermatitis	0.000233	0.00501	CbGpPWpGaD
Amphetamine—Dizziness—Triamcinolone—atopic dermatitis	0.000231	0.000747	CcSEcCtD
Amphetamine—Dizziness—Methylprednisolone—atopic dermatitis	0.000231	0.000745	CcSEcCtD
Amphetamine—Asthenia—Dexamethasone—atopic dermatitis	0.000228	0.000735	CcSEcCtD
Amphetamine—Asthenia—Betamethasone—atopic dermatitis	0.000228	0.000735	CcSEcCtD
Amphetamine—SLC6A4—Circadian rythm related genes—NPS—atopic dermatitis	0.000226	0.00488	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Prednisone—atopic dermatitis	0.000226	0.00073	CcSEcCtD
Amphetamine—Nausea—Prednisolone—atopic dermatitis	0.000226	0.000729	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—CCL11—atopic dermatitis	0.000224	0.00483	CbGpPWpGaD
Amphetamine—Vomiting—Triamcinolone—atopic dermatitis	0.000222	0.000718	CcSEcCtD
Amphetamine—Vomiting—Methylprednisolone—atopic dermatitis	0.000222	0.000716	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—FCER2—atopic dermatitis	0.000221	0.00476	CbGpPWpGaD
Amphetamine—Nausea—Hydrocortisone—atopic dermatitis	0.000221	0.000712	CcSEcCtD
Amphetamine—Rash—Triamcinolone—atopic dermatitis	0.00022	0.000712	CcSEcCtD
Amphetamine—Dermatitis—Triamcinolone—atopic dermatitis	0.00022	0.000711	CcSEcCtD
Amphetamine—Rash—Methylprednisolone—atopic dermatitis	0.00022	0.00071	CcSEcCtD
Amphetamine—Dermatitis—Methylprednisolone—atopic dermatitis	0.00022	0.00071	CcSEcCtD
Amphetamine—Urticaria—Prednisone—atopic dermatitis	0.000219	0.000709	CcSEcCtD
Amphetamine—Headache—Triamcinolone—atopic dermatitis	0.000219	0.000707	CcSEcCtD
Amphetamine—SLC6A2—Monoamine Transport—TNF—atopic dermatitis	0.000219	0.00472	CbGpPWpGaD
Amphetamine—Headache—Methylprednisolone—atopic dermatitis	0.000219	0.000706	CcSEcCtD
Amphetamine—Body temperature increased—Prednisone—atopic dermatitis	0.000218	0.000705	CcSEcCtD
Amphetamine—Abdominal pain—Prednisone—atopic dermatitis	0.000218	0.000705	CcSEcCtD
Amphetamine—Diarrhoea—Dexamethasone—atopic dermatitis	0.000217	0.000701	CcSEcCtD
Amphetamine—Diarrhoea—Betamethasone—atopic dermatitis	0.000217	0.000701	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—CCL5—atopic dermatitis	0.000216	0.00466	CbGpPWpGaD
Amphetamine—Dizziness—Betamethasone—atopic dermatitis	0.00021	0.000677	CcSEcCtD
Amphetamine—Dizziness—Dexamethasone—atopic dermatitis	0.00021	0.000677	CcSEcCtD
Amphetamine—Nausea—Triamcinolone—atopic dermatitis	0.000208	0.000671	CcSEcCtD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL22—atopic dermatitis	0.000207	0.00447	CbGpPWpGaD
Amphetamine—Nausea—Methylprednisolone—atopic dermatitis	0.000207	0.000669	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—CCL22—atopic dermatitis	0.000205	0.00442	CbGpPWpGaD
Amphetamine—Hypersensitivity—Prednisone—atopic dermatitis	0.000204	0.000657	CcSEcCtD
Amphetamine—Vomiting—Betamethasone—atopic dermatitis	0.000202	0.000651	CcSEcCtD
Amphetamine—Vomiting—Dexamethasone—atopic dermatitis	0.000202	0.000651	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—CCR3—atopic dermatitis	0.000201	0.00433	CbGpPWpGaD
Amphetamine—Rash—Betamethasone—atopic dermatitis	0.0002	0.000646	CcSEcCtD
Amphetamine—Rash—Dexamethasone—atopic dermatitis	0.0002	0.000646	CcSEcCtD
Amphetamine—Dermatitis—Betamethasone—atopic dermatitis	0.0002	0.000645	CcSEcCtD
Amphetamine—Dermatitis—Dexamethasone—atopic dermatitis	0.0002	0.000645	CcSEcCtD
Amphetamine—Headache—Betamethasone—atopic dermatitis	0.000199	0.000642	CcSEcCtD
Amphetamine—Headache—Dexamethasone—atopic dermatitis	0.000199	0.000642	CcSEcCtD
Amphetamine—Asthenia—Prednisone—atopic dermatitis	0.000198	0.00064	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—BDNF—atopic dermatitis	0.000197	0.00425	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—CCR5—atopic dermatitis	0.000195	0.0042	CbGpPWpGaD
Amphetamine—SLC6A3—Monoamine Transport—TNF—atopic dermatitis	0.000194	0.00418	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC11A1—atopic dermatitis	0.000193	0.00415	CbGpPWpGaD
Amphetamine—Diarrhoea—Prednisone—atopic dermatitis	0.000189	0.00061	CcSEcCtD
Amphetamine—Nausea—Dexamethasone—atopic dermatitis	0.000188	0.000609	CcSEcCtD
Amphetamine—Nausea—Betamethasone—atopic dermatitis	0.000188	0.000609	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL10—atopic dermatitis	0.000188	0.00406	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL27—atopic dermatitis	0.000185	0.00398	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCL27—atopic dermatitis	0.000183	0.00394	CbGpPWpGaD
Amphetamine—Dizziness—Prednisone—atopic dermatitis	0.000183	0.00059	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—CCR3—atopic dermatitis	0.000183	0.00393	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—NPS—atopic dermatitis	0.000179	0.00386	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—TAC1—atopic dermatitis	0.000179	0.00386	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CXCR3—atopic dermatitis	0.000176	0.00379	CbGpPWpGaD
Amphetamine—Vomiting—Prednisone—atopic dermatitis	0.000176	0.000567	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—NGF—atopic dermatitis	0.000175	0.00377	CbGpPWpGaD
Amphetamine—Rash—Prednisone—atopic dermatitis	0.000174	0.000563	CcSEcCtD
Amphetamine—Dermatitis—Prednisone—atopic dermatitis	0.000174	0.000562	CcSEcCtD
Amphetamine—Headache—Prednisone—atopic dermatitis	0.000173	0.000559	CcSEcCtD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC11A1—atopic dermatitis	0.000171	0.00368	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—IL5—atopic dermatitis	0.000167	0.00359	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL17—atopic dermatitis	0.000166	0.00357	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCL17—atopic dermatitis	0.000164	0.00354	CbGpPWpGaD
Amphetamine—Nausea—Prednisone—atopic dermatitis	0.000164	0.00053	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—TAC1—atopic dermatitis	0.000163	0.00351	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—NPS—atopic dermatitis	0.000163	0.00351	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CXCR3—atopic dermatitis	0.00016	0.00344	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CCL22—atopic dermatitis	0.000158	0.0034	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	0.000155	0.00333	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL5—atopic dermatitis	0.000151	0.00326	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KIF3A—atopic dermatitis	0.000146	0.00315	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	0.000146	0.00314	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CXCL10—atopic dermatitis	0.000142	0.00306	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CCL27—atopic dermatitis	0.000141	0.00303	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—NPS—atopic dermatitis	0.000138	0.00298	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CCR3—atopic dermatitis	0.000137	0.00295	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL11—atopic dermatitis	0.000134	0.00288	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—PPARA—atopic dermatitis	0.000133	0.00287	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCL11—atopic dermatitis	0.000132	0.00285	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CMA1—atopic dermatitis	0.000132	0.00285	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CXCL10—atopic dermatitis	0.000129	0.00278	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—CCR3—atopic dermatitis	0.000127	0.00274	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CCL17—atopic dermatitis	0.000126	0.00272	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	0.000126	0.00271	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	0.000125	0.0027	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—STAT6—atopic dermatitis	0.000124	0.00268	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CCL5—atopic dermatitis	0.000122	0.00263	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CXCR3—atopic dermatitis	0.00012	0.00258	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—CXCL8—atopic dermatitis	0.000118	0.00254	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—CXCR3—atopic dermatitis	0.000111	0.0024	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CCL5—atopic dermatitis	0.000111	0.00239	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CCR5—atopic dermatitis	0.00011	0.00237	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR3—atopic dermatitis	0.000109	0.00235	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCR3—atopic dermatitis	0.000108	0.00232	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GLB1—atopic dermatitis	0.000104	0.00224	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—atopic dermatitis	0.000103	0.00222	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CCL11—atopic dermatitis	0.000102	0.00219	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CCR5—atopic dermatitis	0.0001	0.00216	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ADSL—atopic dermatitis	9.97e-05	0.00215	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL1B—atopic dermatitis	9.88e-05	0.00213	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	9.79e-05	0.00211	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—NPS—atopic dermatitis	9.71e-05	0.00209	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—TAC1—atopic dermatitis	9.71e-05	0.00209	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CXCL10—atopic dermatitis	9.68e-05	0.00209	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NPS—atopic dermatitis	9.61e-05	0.00207	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TAC1—atopic dermatitis	9.61e-05	0.00207	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR3—atopic dermatitis	9.53e-05	0.00205	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CXCR3—atopic dermatitis	9.43e-05	0.00203	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL5—atopic dermatitis	8.94e-05	0.00193	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GLB1—atopic dermatitis	8.8e-05	0.0019	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	8.67e-05	0.00187	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ADSL—atopic dermatitis	8.43e-05	0.00182	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CCL5—atopic dermatitis	8.34e-05	0.0018	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CCR3—atopic dermatitis	8.3e-05	0.00179	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—PPARA—atopic dermatitis	8.16e-05	0.00176	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCL22—atopic dermatitis	8.11e-05	0.00175	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CCL27—atopic dermatitis	7.96e-05	0.00171	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL10—atopic dermatitis	7.7e-05	0.00166	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CXCL10—atopic dermatitis	7.62e-05	0.00164	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CCR5—atopic dermatitis	7.51e-05	0.00162	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—MAPK8—atopic dermatitis	7.4e-05	0.00159	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—TAC1—atopic dermatitis	7.4e-05	0.00159	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—NPS—atopic dermatitis	7.4e-05	0.00159	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CXCR3—atopic dermatitis	7.25e-05	0.00156	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCL27—atopic dermatitis	7.23e-05	0.00156	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—TNF—atopic dermatitis	7.17e-05	0.00154	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—PPARA—atopic dermatitis	7.05e-05	0.00152	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—CCR5—atopic dermatitis	6.97e-05	0.0015	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CXCL8—atopic dermatitis	6.66e-05	0.00144	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL5—atopic dermatitis	6.63e-05	0.00143	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCL5—atopic dermatitis	6.56e-05	0.00141	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCL17—atopic dermatitis	6.48e-05	0.0014	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—IL2—atopic dermatitis	6.37e-05	0.00137	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—PPARA—atopic dermatitis	6.1e-05	0.00131	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—PPARA—atopic dermatitis	6.08e-05	0.00131	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NGF—atopic dermatitis	6.08e-05	0.00131	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CXCL8—atopic dermatitis	6.05e-05	0.0013	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	5.97e-05	0.00129	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCR5—atopic dermatitis	5.91e-05	0.00127	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CXCL10—atopic dermatitis	5.86e-05	0.00126	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL6—atopic dermatitis	5.79e-05	0.00125	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL2—atopic dermatitis	5.78e-05	0.00125	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCL11—atopic dermatitis	5.22e-05	0.00113	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FCER2—atopic dermatitis	5.15e-05	0.00111	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GLB1—atopic dermatitis	5.07e-05	0.00109	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CCL5—atopic dermatitis	5.05e-05	0.00109	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NFKBIA—atopic dermatitis	5.01e-05	0.00108	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ADSL—atopic dermatitis	4.86e-05	0.00105	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCL22—atopic dermatitis	4.79e-05	0.00103	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—PPARA—atopic dermatitis	4.74e-05	0.00102	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—IL6—atopic dermatitis	4.72e-05	0.00102	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CCR3—atopic dermatitis	4.69e-05	0.00101	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CCR5—atopic dermatitis	4.55e-05	0.00098	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CXCL8—atopic dermatitis	4.54e-05	0.000978	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—MAPK8—atopic dermatitis	4.53e-05	0.000975	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCL27—atopic dermatitis	4.27e-05	0.00092	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCR3—atopic dermatitis	4.26e-05	0.000918	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—PPARA—atopic dermatitis	4.2e-05	0.000905	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—TAC1—atopic dermatitis	4.18e-05	0.000901	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—NPS—atopic dermatitis	4.18e-05	0.000901	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCR3—atopic dermatitis	4.1e-05	0.000883	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—IL5—atopic dermatitis	3.89e-05	0.000837	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCL17—atopic dermatitis	3.83e-05	0.000825	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—NPS—atopic dermatitis	3.8e-05	0.000818	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—TAC1—atopic dermatitis	3.8e-05	0.000818	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCR3—atopic dermatitis	3.72e-05	0.000802	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	3.61e-05	0.000778	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CXCL8—atopic dermatitis	3.57e-05	0.00077	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL5—atopic dermatitis	3.53e-05	0.00076	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL2—atopic dermatitis	3.41e-05	0.000736	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KIF3A—atopic dermatitis	3.41e-05	0.000735	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL6—atopic dermatitis	3.4e-05	0.000732	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PPARA—atopic dermatitis	3.37e-05	0.000727	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCL10—atopic dermatitis	3.31e-05	0.000714	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MAPK8—atopic dermatitis	3.14e-05	0.000677	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCL11—atopic dermatitis	3.09e-05	0.000665	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CMA1—atopic dermatitis	3.09e-05	0.000665	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCL10—atopic dermatitis	3.01e-05	0.000648	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STAT6—atopic dermatitis	2.9e-05	0.000625	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—IL6—atopic dermatitis	2.89e-05	0.000623	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PPARA—atopic dermatitis	2.86e-05	0.000615	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CCL5—atopic dermatitis	2.85e-05	0.000614	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GLB1—atopic dermatitis	2.84e-05	0.000612	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CXCL8—atopic dermatitis	2.75e-05	0.000592	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ADSL—atopic dermatitis	2.72e-05	0.000587	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCL5—atopic dermatitis	2.59e-05	0.000558	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CCR5—atopic dermatitis	2.57e-05	0.000554	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCR3—atopic dermatitis	2.52e-05	0.000542	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCR5—atopic dermatitis	2.33e-05	0.000503	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TAC1—atopic dermatitis	2.24e-05	0.000483	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NPS—atopic dermatitis	2.24e-05	0.000483	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCR3—atopic dermatitis	2.2e-05	0.000474	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL5—atopic dermatitis	2.08e-05	0.000449	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL6—atopic dermatitis	2.01e-05	0.000432	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCL10—atopic dermatitis	1.78e-05	0.000383	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPARA—atopic dermatitis	1.64e-05	0.000354	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCL8—atopic dermatitis	1.55e-05	0.000335	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCL5—atopic dermatitis	1.53e-05	0.00033	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—IL2—atopic dermatitis	1.48e-05	0.00032	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NGF—atopic dermatitis	1.42e-05	0.000305	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCL8—atopic dermatitis	1.41e-05	0.000304	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCR5—atopic dermatitis	1.38e-05	0.000297	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL2—atopic dermatitis	1.35e-05	0.00029	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NFKBIA—atopic dermatitis	1.17e-05	0.000252	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPARA—atopic dermatitis	9.22e-06	0.000199	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCL8—atopic dermatitis	8.33e-06	0.00018	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL2—atopic dermatitis	7.96e-06	0.000172	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6—atopic dermatitis	7.92e-06	0.000171	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAPK8—atopic dermatitis	7.33e-06	0.000158	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6—atopic dermatitis	4.68e-06	0.000101	CbGpPWpGaD
